Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 vistas
• 07/18/23
0
0
Empotrar
administrator
Suscriptores
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios